Literature DB >> 28350087

Paclitaxel induces apoptosis of esophageal squamous cell carcinoma cells by downregulating STAT3 phosphorylation at Ser727.

Xiaolong Zhang1, Xiaoyi Wu2, Fangling Zhang3, Shouyong Mo2, Yuanyuan Lu2, Wei Wei2, Xiaoling Chen2, Linhua Lan2, Bin Lu2, Yongzhang Liu2.   

Abstract

Paclitaxel induces apoptosis in a variety of cancer cells. However, the mechanism of paclitaxel inducing apoptosis in human esophageal squamous cell carcinoma (ESCC) remains to be defined. In this study, we found that paclitaxel-induced apoptosis by increasing the relevant apoptosis protein expression and the release of cytochrome c via downregulation of signal transducer and activator of transcription 3 (STAT3) and phospho-STAT3 (Ser727). In addition, paclitaxel treatment of ESCC cells EC-1 and Eca-109 led to marked mitochondrial membrane potential depolarization and significantly increasing of reactive oxygen species. Moreover, paclitaxel treatment resulted in the inhibition of mitochondrial respiration. In conclusion, our findings reveal that paclitaxel induced apoptosis in both EC-1 and Eca-109 cells through the reduction of STAT3 and phospho‑STAT3 (Ser727) level, and suggest that paclitaxel may be of therapeutic potential in the treatment of ESCC through the induction of mitochondrial apoptosis in ESCC cells.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28350087     DOI: 10.3892/or.2017.5503

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  9 in total

1.  Hydrogen Sulfide Is Increased in Oral Squamous Cell Carcinoma Compared to Adjacent Benign Oral Mucosae.

Authors:  Andrew T Meram; Jie Chen; Stavan Patel; Dongsoo D Kim; Brett Shirley; Paul Covello; Domenico Coppola; Eric X Wei; Ghali Ghali; Christopher G Kevil; Rodney E Shackelford
Journal:  Anticancer Res       Date:  2018-07       Impact factor: 2.480

2.  Tim-3 promotes cell aggressiveness and paclitaxel resistance through NF-κB/STAT3 signalling pathway in breast cancer cells.

Authors:  Yizi Cong; Yuxin Cui; Shiguang Zhu; Jianqiao Cao; Haidong Zou; Tracey A Martin; Guangdong Qiao; Wenguo Jiang; Zhigang Yu
Journal:  Chin J Cancer Res       Date:  2020-10-31       Impact factor: 5.087

Review 3.  Mechanisms of cancer cell death induction by paclitaxel: an updated review.

Authors:  Shuang Zhao; Yufei Tang; Ruohan Wang; Masoud Najafi
Journal:  Apoptosis       Date:  2022-07-18       Impact factor: 5.561

4.  Mitochondrial ROS accumulation inhibiting JAK2/STAT3 pathway is a critical modulator of CYT997-induced autophagy and apoptosis in gastric cancer.

Authors:  Ya Cao; Jinglong Wang; Hua Tian; Guo-Hui Fu
Journal:  J Exp Clin Cancer Res       Date:  2020-06-23

5.  Molecular mechanism, regulation, and therapeutic targeting of the STAT3 signaling pathway in esophageal cancer (Review).

Authors:  Rui-Jie Ma; Chao Ma; Kang Hu; Meng-Meng Zhao; Nan Zhang; Zhi-Gang Sun
Journal:  Int J Oncol       Date:  2022-07-20       Impact factor: 5.884

6.  Assessment of Early Growth Response 1 in Tumor Suppression of Esophageal Squamous Cell Carcinoma.

Authors:  Yen-Chiang Tseng; Chih-Wen Shu; Hui-Min Chang; Yi-Hsuan Lin; Yen-Han Tseng; Han-Shui Hsu; Yih-Gang Goan; Ching-Jiunn Tseng
Journal:  J Clin Med       Date:  2022-09-29       Impact factor: 4.964

Review 7.  Breast cancer: Muscarinic receptors as new targets for tumor therapy.

Authors:  Alejandro Español; Agustina Salem; Yamila Sanchez; María Elena Sales
Journal:  World J Clin Oncol       Date:  2021-06-24

8.  PARK2 promotes mitochondrial pathway of apoptosis and antimicrotubule drugs chemosensitivity via degradation of phospho-BCL-2.

Authors:  Hengxing Chen; Yun Li; Yu Li; Zhen Chen; Limin Xie; Wenjia Li; Yuanxin Zhu; Hong Xue; H Phillip Koeffler; Wenjing Wu; Kaishun Hu; Dong Yin
Journal:  Theranostics       Date:  2020-08-08       Impact factor: 11.556

9.  Niclosamide inhibits the cell proliferation and enhances the responsiveness of esophageal cancer cells to chemotherapeutic agents.

Authors:  Ming-Cheng Lee; Yin-Kai Chen; Yih-Jen Hsu; Bor-Ru Lin
Journal:  Oncol Rep       Date:  2019-12-27       Impact factor: 3.906

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.